Validation of biologic markers for use in research on chronic fatigue syndrome.
Schulte, P A · Reviews of infectious diseases · 1991 · DOI
Quick Summary
This paper explains how scientists should evaluate biological markers—measurable signs in blood, tissue, or other body samples—before using them in ME/CFS research. The authors provide a practical checklist that researchers should follow to make sure these markers are reliable, meaningful, and won't be affected by other factors. This helps ensure that future ME/CFS studies measure things accurately and produce trustworthy results.
Why It Matters
For ME/CFS research to move forward, scientists need reliable ways to measure disease activity and biological changes. This paper provides a quality-control framework that helps ensure future ME/CFS biomarker studies will be rigorous and comparable, building stronger evidence for understanding the disease's biological basis and potentially identifying diagnostic tests.
Observed Findings
A comprehensive checklist for evaluating biologic markers is presented
Markers must be evaluated differently depending on whether they serve as dependent or independent variables in research
Assay reliability, background levels, and potential confounding factors must be systematically assessed before marker validation
Legal and ethical implications require consideration in biomarker research
Multiple characteristics beyond statistical association must be evaluated for clinical utility
Inferred Conclusions
Systematic validation frameworks are essential for responsible biologic marker research in chronic disease
Standardized criteria improve comparability and reliability across research studies
Remaining Questions
Which specific biologic markers in ME/CFS meet all criteria on this validation checklist?
How should the checklist be adapted for markers measured in different specimen types (blood, cerebrospinal fluid, tissue)?
What role should patient input play in evaluating whether validated markers are clinically meaningful?
What This Study Does Not Prove
This paper does not identify any specific ME/CFS biomarkers or prove that particular biological markers are valid for the disease. It is a methodological guide, not an empirical study, so it does not present new data about ME/CFS biology itself. The checklist is advisory and does not guarantee that any marker will ultimately be useful in clinical practice.